Braeden William Lichti: Trends in the Aesthetic BioTech Market
/PRNewswire/ — In 1978, scientists isolated human insulin produced by genetically modified E. coli, marking the first biopharmaceutical derived from…
Read More/PRNewswire/ — In 1978, scientists isolated human insulin produced by genetically modified E. coli, marking the first biopharmaceutical derived from…
Read MoreSeattle-based Aurion Biotech is a developer of regenerative therapies for vision loss. Aurion Biotech secured a US$ 120 million financing that was led
…
Verve Therapeutics creates genetic therapies to confer protection against coronary diseases. See why VERV stock presents opportunity for long-term investors.
With no political agenda, just a desire to help, a local biotech company executive signed up for duty at the World Central Kitchens in Poland to feed Ukrainian refugees.
Several catalysts are expected for Inovio in 2022. Read why these developments could improve shareholder value.
Versant Ventures has launched Cimeio Therapeutics, a biotech startup with technology that can shield transplanted stem cells or cell therapies. Shielding these cells enables them to be dosed alongside an immunotherapy—an approach that is not currently …
TG Therapeutics is heading back to the drawing board after new data showed its cancer drug had an elevated risk of death, plucking Ukoniq off the market for the two indications it won accelerated a | TG Therapeutics is heading back to the drawing board…
Some biotechs are building as others crumble, with several industry players—including Alexion Pharmaceuticals and Arvinas—involved in plans for a new 10-floor tower built for burgeoning biotechs. | Some biotechs are building as others crumble, with s…
Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Rating) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 3,700 shares, an increase of 311.1% from the March 15th total of…
Adaptive Biotech product ‘clonoSEQ’ is the first MRD test cleared by FDA for multiple myeloma, CLL, and B-ALL. See why investors should consider adding ADPT stock to their portfolio.